Obsidian Therapeutics, Inc. announced it raised $32.4 Million in an initial filing from an offering of $49.9 Million
Obsidian Therapeutics, Inc. announced it raised $32.4 Million in an initial filing from an offering of $49.9 Million
12/08/17, 3:02 PM
Location
Money raised
$32.4 million
Industry
therapeutics
health care
biotechnology
Company Info
Location
1030 massachusetts avenue
cambridge, massachusetts, united states
Additional Info
Obsidian Therapeutics, Inc. is a clinical biotechnology company pioneering engineered cell and gene therapies to deliver transformative outcomes for patients with intractable diseases. Obsidian’s proprietary cytoDRiVE® technology provides a way to precisely control the timing and level of protein function by using FDA approved small molecules. Obsidian is headquartered in Cambridge, Mass. The Company has collaborations with Bristol Myers Squibb and Vertex Pharmaceuticals. For more information, please visit www.obsidiantx.com and follow us on LinkedIn and Twitter.